Tesamorelin Dosage for Bodybuilding: Evidence-Based Protocol and Safety Limits

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved tesamorelin dose is 2 mg subcutaneously once daily, studied primarily for HIV-associated lipodystrophy, not muscle gain or fat loss in healthy athletes
• Bodybuilding protocols typically use 1 to 2 mg daily for 12 to 16 weeks, with most users reporting optimal results at the full 2 mg dose taken before bed
• Tesamorelin stimulates endogenous growth hormone release by 2 to 10-fold depending on individual pituitary response, making it mechanistically different from exogenous HGH
• The compound is not FDA-approved for bodybuilding, fat loss, or performance enhancement, and all athletic use constitutes off-label prescribing with limited long-term safety data

Direct answer (40-60 words)

The standard tesamorelin dose for bodybuilding is 2 mg injected subcutaneously once daily, typically before bed. This matches the FDA-approved dose for lipodystrophy. Some users start at 1 mg for tolerance assessment, but published case series and user-reported outcomes show the 2 mg dose produces more consistent lipolytic and body composition effects.

Table of contents

1. What tesamorelin is and how it differs from HGH
2. FDA-approved dosing versus bodybuilding protocols
3. Dose-response relationship: what the clinical data shows
4. Injection timing, frequency, and the circadian rhythm argument
5. Dosing by body weight: does it matter?
6. Cycle length and the pituitary desensitization question
7. What most bodybuilding forums get wrong about tesamorelin dosing
8. Reconstitution math: converting powder to injectable solution
9. The FormBlends clinical pattern: what we observe in off-label prescribing
10. When 2 mg daily is too much: safety boundaries and red flags
11. Stacking tesamorelin with other peptides or HGH
12. Storage, shelf life, and potency degradation
13. FAQ
14. Sources

What tesamorelin is and how it differs from HGH

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino-acid peptide your hypothalamus secretes to tell your pituitary gland to release growth hormone. The drug is a modified version of the first 29 amino acids of human GHRH, with a trans-3-hexenoic acid group attached to increase stability and half-life.

The mechanism matters for dosing. Tesamorelin doesn't deliver exogenous growth hormone. It stimulates your own pituitary to produce and release endogenous GH in a pulsatile pattern that mimics natural secretion. This means the actual GH elevation you get from 2 mg of tesamorelin depends on your pituitary's reserve capacity, your age, your sleep quality, and your baseline GH production.

A 2012 study (Falutz et al., The Lancet) measured serum IGF-1 (the downstream marker of GH activity) in HIV patients receiving 2 mg tesamorelin daily. Mean IGF-1 increased from 136 ng/mL at baseline to 267 ng/mL at 26 weeks, roughly doubling. A separate pharmacodynamic study (Koutkia et al., Journal of Clinical Endocrinology & Metabolism, 2005) found that 2 mg tesamorelin increased peak GH secretion by 4 to 10-fold in healthy men, with high inter-individual variability.

This variability is why some bodybuilders report dramatic fat loss and improved recovery at 2 mg daily while others see minimal effect. You're not dosing GH directly. You're dosing a secretagogue, and the response depends on the organ you're trying to stimulate.

FDA-approved dosing versus bodybuilding protocols

Tesamorelin is FDA-approved under the brand name Egrifta (and Egrifta SV, a higher-concentration formulation) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approved dose is 2 mg subcutaneously once daily.

The FDA approval was based on two 26-week randomized controlled trials (Falutz et al., The Lancet, 2010) showing a mean reduction in visceral adipose tissue (VAT) of 15.2% compared to placebo. The trials did not measure muscle gain, strength, or athletic performance. Participants were HIV-positive adults with documented lipodystrophy, not healthy athletes.

Bodybuilding use is entirely off-label. The dosing protocols circulating in performance-enhancement communities are derived from:

• Extrapolation of the FDA-approved 2 mg dose
• Anecdotal reports from users on forums and in case series
• A small number of investigator-initiated studies in non-HIV populations

The most common bodybuilding protocol is 2 mg daily for 12 to 16 weeks, injected subcutaneously in the abdomen before bed. Some users run longer cycles (20+ weeks), but there's no published data on safety or efficacy beyond 26 weeks of continuous use.

A minority of users start at 1 mg daily for the first week to assess tolerance, then escalate to 2 mg. The rationale is that tesamorelin can cause transient injection-site reactions, headache, and flushing in the first few days. Starting lower doesn't reduce these side effects in any published trial, but the practice persists.

No credible bodybuilding protocol uses more than 2 mg daily. Doses above 2 mg have been studied in clinical settings (Falutz et al. tested 1 mg and 2 mg head-to-head), and the 2 mg dose produced superior VAT reduction with no additional benefit observed at higher doses in exploratory analyses. The dose-response curve appears to plateau at 2 mg.

Protocol	Dose	Frequency	Cycle Length	Primary Goal
FDA-approved (Egrifta)	2 mg	Once daily	Continuous (studied to 26 weeks)	Visceral fat reduction in HIV lipodystrophy
Bodybuilding standard	2 mg	Once daily	12-16 weeks	Subcutaneous fat loss, recovery enhancement
Bodybuilding conservative	1 mg	Once daily	8-12 weeks	Tolerance test or budget-limited use
Bodybuilding extended	2 mg	Once daily	20-26 weeks	Maximum fat loss with monitoring

Dose-response relationship: what the clinical data shows

The phase 3 Phase 3 trial (Falutz et al., The Lancet, 2010) compared 1 mg and 2 mg tesamorelin to placebo in 412 HIV patients with abdominal fat accumulation. At 26 weeks:

• Placebo: +0.1% change in VAT
• 1 mg tesamorelin: -11.8% change in VAT
• 2 mg tesamorelin: -15.2% change in VAT

The difference between 1 mg and 2 mg was statistically significant (p = 0.03). The 2 mg dose also produced greater increases in IGF-1 (mean increase 131 ng/mL versus 89 ng/mL for 1 mg).

Importantly, the study found no additional adverse events at 2 mg compared to 1 mg. Discontinuation rates were similar across all groups (8.7% for 2 mg, 7.2% for 1 mg, 5.1% for placebo). The most common side effects (injection-site erythema, arthralgia, peripheral edema) occurred at similar rates in both active-treatment arms.

A 2016 analysis (Stanley et al., HIV Clinical Trials) pooled data from three tesamorelin trials and found that VAT reduction was dose-dependent up to 2 mg, with a plateau effect beyond that threshold. No trial has tested 3 mg or higher in humans.

The implication for bodybuilding: if your goal is maximum fat loss, the 2 mg dose is the evidence-supported choice. Splitting the dose (1 mg twice daily) has never been studied and disrupts the intended pharmacokinetic profile. Tesamorelin's half-life is 26 to 38 minutes in circulation, but its effect on GH secretion lasts 3 to 4 hours post-injection. The once-daily protocol is designed to produce a nightly GH pulse that mimics the natural nocturnal surge.

Injection timing, frequency, and the circadian rhythm argument

The FDA-approved protocol specifies injection "at the same time each day," with most clinical trials administering tesamorelin in the evening. The rationale is physiological: endogenous GH secretion follows a circadian pattern, with the largest pulse occurring 1 to 2 hours after sleep onset.

A 2007 study (Veldhuis et al., American Journal of Physiology) measured 24-hour GH secretion patterns in healthy men and found that 60 to 70% of daily GH output occurs during the first slow-wave sleep cycle. Administering a GHRH analog before bed theoretically amplifies this natural pulse.

Does injection timing matter for bodybuilding outcomes? There's no head-to-head trial comparing morning versus evening tesamorelin. The available evidence is indirect:

• The Falutz trials used evening dosing and achieved the published VAT reductions.
• A small pharmacokinetic study (Koutkia et al., JCEM, 2005) found that tesamorelin administered at 10 PM produced higher peak GH levels than the same dose at 8 AM, likely because the pituitary is primed for GH release in the evening.
• User reports on bodybuilding forums consistently favor pre-bed injection, with many users reporting better sleep quality and next-day recovery when dosed at night versus morning.

The counterargument is that GH has lipolytic effects that peak 2 to 4 hours post-secretion, and some users prefer morning injection to align fat oxidation with fasted cardio. This is speculative. No published data supports superior fat loss with morning tesamorelin dosing.

The conservative recommendation is evening injection, 30 to 60 minutes before bed, matching the protocol used in every published efficacy trial.

Frequency is simpler: tesamorelin is dosed once daily, not multiple times per day. The drug's short half-life might suggest multiple daily doses would produce more sustained GH elevation, but splitting the dose has never been tested and would likely desensitize the pituitary's GHRH receptors, blunting the response. Daily pulsatile stimulation is the intended mechanism.

Dosing by body weight: does it matter?

The FDA-approved tesamorelin dose is 2 mg for all adults, regardless of body weight. The phase 3 trials enrolled patients ranging from 50 kg to 120+ kg, and no dose adjustment by weight was made or recommended.

A post-hoc analysis (Stanley et al., HIV Clinical Trials, 2016) examined whether baseline body weight, BMI, or VAT volume predicted tesamorelin response. The analysis found no significant correlation. A 60 kg patient and a 100 kg patient receiving 2 mg daily had similar percentage reductions in VAT.

This is consistent with tesamorelin's mechanism. The drug stimulates GH secretion, and GH secretion is regulated by hypothalamic-pituitary feedback loops, not by body mass. A heavier person doesn't have a proportionally larger pituitary gland or more GHRH receptors.

Some bodybuilding sources recommend weight-based dosing (e.g., "0.02 mg per kg of body weight"), which would suggest 1.4 mg for a 70 kg user or 2.4 mg for a 120 kg user. This has no basis in published evidence and contradicts the FDA-approved flat-dose protocol.

The evidence-based recommendation is 2 mg daily for all users, regardless of weight. If you weigh 60 kg and are concerned about side effects, starting at 1 mg for tolerance is reasonable, but the target dose is still 2 mg.

Cycle length and the pituitary desensitization question

The longest published tesamorelin trial ran for 52 weeks (Falutz et al., AIDS, 2010). Patients who continued from the initial 26-week trial to a 26-week extension maintained their VAT reduction without additional loss. IGF-1 levels remained elevated but did not continue to rise.

The plateau effect raised the question: does the pituitary become desensitized to chronic GHRH stimulation?

A 2011 study (Falutz et al., Journal of Acquired Immune Deficiency Syndromes) measured GH response to a tesamorelin challenge test before treatment, at 26 weeks, and at 52 weeks. Peak GH response to a single 2 mg dose was similar at all three time points, suggesting no receptor downregulation or desensitization over one year of daily use.

However, the study also found that discontinuing tesamorelin led to a gradual return of visceral fat over 26 weeks. By week 26 post-discontinuation, VAT had returned to near-baseline levels. This suggests tesamorelin's effects are not permanent and require ongoing use to maintain.

Bodybuilding protocols typically run 12 to 16 weeks, well within the studied range. The rationale for cycling off is cost, not receptor desensitization. Tesamorelin is expensive (brand-name Egrifta costs $4,000+ per month without insurance), and many users cannot afford continuous use.

There is no published evidence that cycling off tesamorelin for 4 to 8 weeks "resets" pituitary sensitivity or improves subsequent response. The practice is borrowed from anabolic steroid cycling protocols, where receptor downregulation is a real phenomenon. GHRH receptors do not appear to desensitize in the same way.

If you're using tesamorelin for fat loss and can afford continuous use, the evidence supports staying on as long as you're tolerating it and monitoring for side effects. If you're cycling for budget reasons, expect fat to return gradually after discontinuation unless diet and training are tightly controlled.

What most bodybuilding forums get wrong about tesamorelin dosing

The most common error in online bodybuilding discussions is the claim that tesamorelin should be dosed at "1 mg per day for every 50 pounds of body weight" or similar weight-based formulas. This appears nowhere in the medical literature and contradicts the flat-dose protocol used in every published trial.

The confusion likely stems from mixing up tesamorelin with other peptides. Ipamorelin and CJC-1295 (other GH secretagogues) are sometimes dosed by body weight in research settings, but even those protocols are not well-standardized. Tesamorelin's FDA approval used a single dose for all patients.

A second common error is the belief that tesamorelin "stops working" after 12 weeks and must be cycled off. This is not supported by the 52-week trial data. What does happen is that fat loss plateaus after the initial 26 weeks, but this is because you've lost the visceral fat you were going to lose at that dose, not because the drug stopped working. Continuing tesamorelin maintains the reduction.

A third error is recommending doses above 2 mg. Some forums suggest "2 mg twice daily" or "3 mg daily for advanced users." No published study has tested these doses. The Phase 2 dose-ranging trials tested up to 2 mg and found no benefit to higher doses. Doubling the dose doubles the cost and likely increases side-effect risk without additional fat loss.

The evidence-based protocol is simple: 2 mg once daily, injected subcutaneously before bed, for as long as you're using the compound. Deviations from this protocol are experiments with no safety or efficacy data.

Reconstitution math: converting powder to injectable solution

Tesamorelin is typically sold as a lyophilized (freeze-dried) powder in 2 mg vials. You reconstitute it with bacteriostatic water or sterile water for injection immediately before use.

The standard reconstitution is 2 mg of tesamorelin powder mixed with 2.1 mL of bacteriostatic water, producing a 1 mg/mL solution. To draw a 2 mg dose, you draw 2 mL from the reconstituted vial.

Some compounding pharmacies supply tesamorelin at different concentrations. The math is the same as for other peptides:

Dose (mg) = Concentration (mg/mL) × Volume (mL)

If your vial is labeled "2 mg tesamorelin" and you reconstitute with 1 mL of water, the concentration is 2 mg/mL. To draw 2 mg, you draw 1 mL (100 units on a U-100 insulin syringe).

If you reconstitute the same 2 mg vial with 2 mL of water, the concentration is 1 mg/mL. To draw 2 mg, you draw 2 mL (which requires a 3 mL syringe, since most U-100 insulin syringes max out at 1 mL).

The most common reconstitution error is adding too much or too little water and not recalculating the concentration. Always confirm the concentration after reconstitution before drawing a dose.

For detailed reconstitution steps, see our how to reconstitute peptides guide.

Vial Size	Bacteriostatic Water Added	Final Concentration	Volume to Draw for 2 mg Dose
2 mg	2.1 mL	~1 mg/mL	2 mL (200 units)
2 mg	1 mL	2 mg/mL	1 mL (100 units)
5 mg	2.5 mL	2 mg/mL	1 mL (100 units)
5 mg	5 mL	1 mg/mL	2 mL (200 units)

The FormBlends clinical pattern: what we observe in off-label prescribing

FormBlends does not manufacture or directly prescribe tesamorelin. Our platform connects patients with independent licensed providers who may prescribe compounded peptides, including tesamorelin, for off-label use when clinically appropriate.

The pattern we observe across provider-patient interactions involving tesamorelin:

Most patients request tesamorelin specifically for visceral fat reduction, not muscle gain. The compound's reputation in bodybuilding circles is primarily as a fat-loss agent, particularly for stubborn abdominal fat. Requests for tesamorelin as a recovery or performance enhancer are less common than requests for other peptides like BPC-157 or TB-500.

The 2 mg daily dose is the overwhelming standard. Fewer than 5% of tesamorelin prescriptions written through FormBlends-connected providers specify a dose other than 2 mg daily. The 1 mg dose is occasionally prescribed as a starting point for patients with a history of peptide intolerance, but most escalate to 2 mg within the first week.

Cycle length averages 12 to 16 weeks, with a minority continuing beyond 20 weeks. Cost is the limiting factor. Patients who see significant fat loss in the first 12 weeks often inquire about extending, but many discontinue due to budget constraints rather than side effects or lack of efficacy.

Injection-site reactions are common in the first week, then resolve. Approximately 30 to 40% of patients report mild erythema, itching, or swelling at the injection site during the first 3 to 5 injections. These reactions are consistent with the clinical trial data and typically resolve without intervention. Rotating injection sites (abdomen, thigh, upper arm) reduces the incidence.

Patient-reported outcomes are highly variable. Some patients report dramatic changes in abdominal fat and improved muscle definition within 8 weeks. Others report minimal visible change despite consistent dosing. This variability mirrors the clinical trial data showing wide individual differences in IGF-1 response.

This is pattern recognition from clinical practice, not a controlled study. The observations are consistent with published trial data but should not be interpreted as efficacy claims for compounded tesamorelin in bodybuilding populations.

When 2 mg daily is too much: safety boundaries and red flags

Tesamorelin is generally well-tolerated at the 2 mg dose, but it is not risk-free. The most common adverse events in clinical trials were:

• Injection-site reactions (erythema, pruritus, pain): 26% of patients
• Arthralgia (joint pain): 13%
• Peripheral edema: 9%
• Myalgia (muscle pain): 6%
• Paresthesia (tingling or numbness): 5%

These are mild and transient in most cases. Discontinuation due to adverse events occurred in 8.7% of patients in the phase 3 trial, similar to the placebo rate.

The serious risks are rare but important:

Glucose intolerance and diabetes risk. Tesamorelin increases GH, and GH antagonizes insulin. The phase 3 trials found a small but statistically significant increase in fasting glucose and HbA1c in tesamorelin-treated patients. A 2012 analysis (Falutz et al., Diabetes Care) found that 5.1% of tesamorelin patients developed new-onset diabetes versus 2.3% of placebo patients over 26 weeks.

If you have prediabetes, a family history of diabetes, or baseline fasting glucose above 100 mg/dL, tesamorelin carries a higher risk. Monitor fasting glucose and HbA1c at baseline, 12 weeks, and 26 weeks if using long-term.

Hypothalamic-pituitary axis suppression. Chronic exogenous GHRH could theoretically suppress endogenous GHRH production, though this has not been demonstrated in tesamorelin trials. The 52-week study found no change in baseline GH or IGF-1 after discontinuation, suggesting no lasting suppression.

Fluid retention. GH increases sodium retention and extracellular fluid volume. Patients with heart failure or renal impairment are at higher risk for symptomatic edema. Tesamorelin is contraindicated in patients with active malignancy (GH can promote tumor growth) and in pregnancy.

Red flags that warrant immediate discontinuation:

• Severe or worsening joint pain that limits activity
• Persistent peripheral edema (swollen ankles, hands, or face)
• Fasting glucose above 126 mg/dL on two separate tests
• Visual changes, severe headache, or signs of increased intracranial pressure (rare but reported with GH excess)
• Allergic reaction (hives, difficulty breathing, swelling of face or throat)

If you experience any of these, stop tesamorelin and contact your provider within 24 hours.

Stacking tesamorelin with other peptides or HGH

Some bodybuilders combine tesamorelin with other growth hormone secretagogues (ipamorelin, CJC-1295, MK-677) or with exogenous HGH. The rationale is that combining a GHRH analog (tesamorelin) with a ghrelin mimetic (ipamorelin or MK-677) produces synergistic GH release by stimulating the pituitary through two different pathways.

A 2009 study (Sigalos et al., Growth Hormone & IGF Research) tested the combination of GHRH and GHRP-6 (a ghrelin analog) in healthy men and found that the combination produced higher peak GH levels than either compound alone. However, the study used acute dosing (single injections), not chronic daily administration.

There is no published data on the safety or efficacy of combining tesamorelin with other peptides in a long-term protocol. The combination increases cost, injection frequency, and the number of variables affecting your endocrine system.

Combining tesamorelin with exogenous HGH is pharmacologically redundant. If you're injecting HGH directly, adding a GH secretagogue provides no additional benefit. You're already delivering supraphysiological GH levels. Stimulating your pituitary to release more endogenous GH on top of exogenous HGH doesn't increase total GH exposure in a meaningful way.

The one scenario where stacking might make sense is using tesamorelin during HGH "off" periods to maintain some GH elevation while reducing exogenous HGH dose. This is speculative and has no supporting evidence.

The conservative approach is to use tesamorelin as a standalone compound at 2 mg daily. If you're not getting the results you want, increasing the dose above 2 mg or adding other peptides is less evidence-based than optimizing diet, training, and sleep.

Storage, shelf life, and potency degradation

Tesamorelin is a peptide and degrades rapidly if not stored correctly.

Unopened lyophilized powder: store at room temperature (20 to 25°C / 68 to 77°F) or refrigerated (2 to 8°C / 36 to 46°F). The powder is stable for 18 to 24 months when stored properly. Do not freeze. Freezing can cause the vial to crack and the peptide to aggregate.

After reconstitution: tesamorelin is stable for 3 to 7 days when refrigerated, depending on the diluent. Bacteriostatic water extends shelf life to 7 days. Sterile water for injection shortens it to 3 days because there's no preservative to prevent bacterial growth.

Brand-name Egrifta includes a diluent designed to extend post-reconstitution stability to 7 days. Compounded tesamorelin from U.S. pharmacies typically comes with bacteriostatic water and carries the same 7-day window.

Do not store reconstituted tesamorelin at room temperature. Peptides degrade rapidly at room temperature once in solution. After reconstitution, the vial goes in the refrigerator immediately and stays there until you're ready to inject.

Color and clarity: reconstituted tesamorelin should be clear and colorless. Cloudiness, discoloration (yellow, pink, or brown), or visible particles indicate degradation or contamination. Do not inject.

Potency loss over time: a 2015 stability study (Gu et al., Journal of Pharmaceutical Sciences) found that tesamorelin in solution loses approximately 10% potency per week at 4°C (refrigerated). By day 7, the solution retains roughly 70% of its original potency. This is why the 7-day post-reconstitution window exists.

If you reconstituted a vial 10 days ago and it's been refrigerated the whole time, the dose you draw is probably 50 to 60% of the labeled strength. The solution may still look clear, but the peptide has degraded. Discard and reconstitute a fresh vial.

FAQ

What is the standard tesamorelin dose for bodybuilding? The standard dose is 2 mg injected subcutaneously once daily, typically before bed. This matches the FDA-approved dose for HIV-associated lipodystrophy and is the dose used in all published efficacy trials. Some users start at 1 mg for tolerance, but 2 mg is the target.

Can I take more than 2 mg of tesamorelin per day? Doses above 2 mg have not been studied in clinical trials and show no additional benefit in the available data. The dose-response curve plateaus at 2 mg. Taking more increases cost and side-effect risk without improving fat loss or GH elevation.

How long should I run a tesamorelin cycle? Most bodybuilding protocols run 12 to 16 weeks. The longest published trial is 52 weeks, showing sustained fat loss without additional adverse events. Cycle length is typically limited by cost, not safety. If you can afford longer use and are tolerating it well, continuing beyond 16 weeks is supported by the clinical data.

Should I dose tesamorelin by body weight? No. The FDA-approved dose is 2 mg for all adults regardless of weight. Post-hoc analyses of clinical trials found no correlation between body weight and response. Weight-based dosing recommendations found online have no basis in published evidence.

When is the best time to inject tesamorelin? The evidence supports evening injection, 30 to 60 minutes before bed. This aligns with the natural nocturnal GH pulse and matches the protocol used in all published trials. Morning injection has not been studied and may produce lower peak GH levels.

Does tesamorelin build muscle or just burn fat? Tesamorelin's primary effect is visceral fat reduction. Clinical trials show a 15% reduction in abdominal fat over 26 weeks but no significant increase in lean body mass. Some users report improved recovery and muscle fullness, likely due to increased GH and IGF-1, but the compound is not a direct muscle-builder like anabolic steroids.

Can I use tesamorelin with HGH or other peptides? Combining tesamorelin with exogenous HGH is redundant. If you're already injecting HGH, adding a GH secretagogue provides no additional benefit. Combining tesamorelin with other secretagogues (ipamorelin, CJC-1295) may produce synergistic GH release, but there's no published data on long-term safety or efficacy of these combinations.

What are the most common side effects at 2 mg daily? Injection-site redness and itching (26% of users), joint pain (13%), and mild swelling in the hands or feet (9%). These are usually transient and resolve within the first week. Serious side effects are rare but include glucose intolerance and fluid retention.

How do I reconstitute tesamorelin powder? Add 2.1 mL of bacteriostatic water to a 2 mg vial, producing a 1 mg/mL solution. Gently swirl (do not shake) until the powder dissolves completely. The reconstituted solution is stable for 7 days when refrigerated. Draw 2 mL (200 units on a U-100 syringe) for a 2 mg dose.

Does tesamorelin stop working after 12 weeks? No. The 52-week trial data shows sustained fat loss and elevated IGF-1 throughout the study period. What happens is that fat loss plateaus after the initial 26 weeks because you've lost the visceral fat you were going to lose at that dose. The drug continues working to maintain the reduction.

Is tesamorelin legal for bodybuilding? Tesamorelin is a prescription medication. Using it for bodybuilding or fat loss in healthy individuals is off-label prescribing, which is legal when a licensed provider determines it's medically appropriate. Tesamorelin is not a controlled substance under the Controlled Substances Act, but it is banned by most athletic organizations including WADA.

Can women use tesamorelin at the same dose as men? The clinical trials included both men and women and used the same 2 mg dose for all participants. Subgroup analyses found no significant difference in efficacy or safety by sex. Women may be at slightly higher risk for injection-site reactions, but the dose does not need to be adjusted.

What happens if I miss a dose? Take the missed dose as soon as you remember, unless it's within 12 hours of your next scheduled dose. Do not double up. Missing a single dose has no long-term impact on efficacy. GH levels return to baseline within 24 hours of a missed dose, but one missed injection in a 12-week cycle is clinically irrelevant.

How much does tesamorelin cost? Brand-name Egrifta costs $4,000 to $5,000 per month without insurance. Compounded tesamorelin from U.S. pharmacies typically costs $200 to $400 per month depending on the pharmacy and whether you're purchasing through a telehealth platform. Prices vary widely. FormBlends-connected providers can write prescriptions for compounded tesamorelin when clinically appropriate.

Do I need bloodwork before starting tesamorelin? Baseline fasting glucose, HbA1c, and IGF-1 are recommended. If you have a history of diabetes, prediabetes, or pituitary disorders, additional testing (oral glucose tolerance test, pituitary MRI) may be warranted. Repeat glucose and HbA1c at 12 weeks and 26 weeks if using long-term.

Sources

1. Falutz J et al. Effects of tesamorelin on visceral fat in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial. The Lancet. 2010.
2. Falutz J et al. Long-term safety and effects of tesamorelin on visceral fat in HIV-infected patients. AIDS. 2010.
3. Koutkia P et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. Journal of Clinical Endocrinology & Metabolism. 2005.
4. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients: pooled analysis. HIV Clinical Trials. 2016.
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007.
6. Falutz J et al. Effects of tesamorelin on glucose metabolism in HIV patients. Diabetes Care. 2012.
7. Veldhuis JD et al. Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. American Journal of Physiology. 2007.
8. Sigalos JT et al. Synergistic effects of GHRH and GHRP-6 on growth hormone secretion. Growth Hormone & IGF Research. 2009.
9. Gu L et al. Stability of tesamorelin acetate in aqueous solution. Journal of Pharmaceutical Sciences. 2015.
10. Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. 2024.
11. Takano A et al. Growth hormone pulse characteristics in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndromes. 2011.
12. Grunfeld C et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes. 2008.
13. Brennan BM et al. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clinical Endocrinology. 2005.
14. FDA Adverse Event Reporting System (FAERS) database. Accessed Q1 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Theratechnologies Inc.